These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 16934840)
1. Use of effect size to determine optimal dose of duloxetine in major depressive disorder. Pritchett YL; Marciniak MD; Corey-Lisle PK; Berzon RA; Desaiah D; Detke MJ J Psychiatr Res; 2007; 41(3-4):311-8. PubMed ID: 16934840 [TBL] [Abstract][Full Text] [Related]
2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385 [TBL] [Abstract][Full Text] [Related]
3. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder. Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729 [TBL] [Abstract][Full Text] [Related]
4. Duloxetine 60 mg once daily in the treatment of milder major depressive disorder. Perahia DG; Kajdasz DK; Walker DJ; Raskin J; Tylee A Int J Clin Pract; 2006 May; 60(5):613-20. PubMed ID: 16700869 [TBL] [Abstract][Full Text] [Related]
5. Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression. Shelton RC; Prakash A; Mallinckrodt CH; Wohlreich MM; Raskin J; Robinson MJ; Detke MJ Int J Clin Pract; 2007 Aug; 61(8):1337-48. PubMed ID: 17627710 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. Perahia DG; Pritchett YL; Kajdasz DK; Bauer M; Jain R; Russell JM; Walker DJ; Spencer KA; Froud DM; Raskin J; Thase ME J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831 [TBL] [Abstract][Full Text] [Related]
7. Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Nelson JC Depress Anxiety; 2010; 27(1):12-8. PubMed ID: 20013987 [TBL] [Abstract][Full Text] [Related]
8. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641 [TBL] [Abstract][Full Text] [Related]
9. Comparisons of the efficacy and safety of duloxetine for the treatment of fibromyalgia in patients with versus without major depressive disorder. Arnold LM; Hudson JI; Wang F; Wohlreich MM; Prakash A; Kajdasz DK; Chappell AS Clin J Pain; 2009; 25(6):461-8. PubMed ID: 19542792 [TBL] [Abstract][Full Text] [Related]
10. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features. Mallinckrodt CH; Watkin JG; Liu C; Wohlreich MM; Raskin J BMC Psychiatry; 2005 Jan; 5():1. PubMed ID: 15631624 [TBL] [Abstract][Full Text] [Related]
11. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. Stewart DE; Wohlreich MM; Mallinckrodt CH; Watkin JG; Kornstein SG J Affect Disord; 2006 Aug; 94(1-3):183-9. PubMed ID: 16780958 [TBL] [Abstract][Full Text] [Related]
12. The effect of pain on outcomes in a trial of duloxetine treatment of major depressive disorder. Arnold LM; Meyers AL; Sunderajan P; Montano CB; Kass E; Trivedi M; Wohlreich MM Ann Clin Psychiatry; 2008; 20(4):187-93. PubMed ID: 19034749 [TBL] [Abstract][Full Text] [Related]
13. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599 [TBL] [Abstract][Full Text] [Related]
15. Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression. Cowen PJ; Ogilvie AD; Gama J Curr Med Res Opin; 2005 Mar; 21(3):345-56. PubMed ID: 15811202 [TBL] [Abstract][Full Text] [Related]
16. Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorder. Fava M; Wiltse C; Walker D; Brecht S; Chen A; Perahia D J Affect Disord; 2009 Mar; 113(3):263-71. PubMed ID: 18625521 [TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson JI; Wohlreich MM; Kajdasz DK; Mallinckrodt CH; Watkin JG; Martynov OV Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562 [TBL] [Abstract][Full Text] [Related]
18. Factors predicting reduced antidepressant response: experience with the SNRI duloxetine in patients with major depression. Howland RH; Wilson MG; Kornstein SG; Clayton AH; Trivedi MH; Wohlreich MM; Fava M Ann Clin Psychiatry; 2008; 20(4):209-18. PubMed ID: 19034753 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Rynn M; Russell J; Erickson J; Detke MJ; Ball S; Dinkel J; Rickels K; Raskin J Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303 [TBL] [Abstract][Full Text] [Related]
20. Duloxetine versus placebo in the treatment of major depressive disorder and associated painful physical symptoms: a replication study. Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Hann D; Marangell LB Curr Med Res Opin; 2011 Oct; 27(10):1859-67. PubMed ID: 21838410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]